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Background: Altered perfusion might play an important role in the pathophysiology of patellofemoral pain (PFP), a
common knee complaint with unclear pathophysiology.
Purpose: To investigate differences in dynamic contrast-enhanced (DCE)-MRI perfusion parameters between patients
with PFP and healthy control subjects.
Population/Subjects/Phantom/Specimen/Animal Model: Thirty-five adult patients with PFP and 44 healthy adult con-
trol subjects.
Field Strength/Sequence: 3T DCE-MRI consisting of a sagittal, anterior-posterior, frequency-encoded, fat-suppressed
3D spoiled gradient-echo sequence with intravenous contrast administration.
Assessment: Patellar bone volumes of interest (VOIs) were delineated by a blinded observer. Quantitative perfusion
parameters (kep and ktrans) were calculated from motion-compensated DCE-MRI data by fitting Tofts’ model. Weighted
mean and unweighted median values of kep and ktrans were computed within the patellar bone VOIs.
Statistical Tests: Differences in patellar bone perfusion parameters were compared between groups by linear regression
analyses, adjusted for confounders.
Results: Mean differences of weighted mean and unweighted median were 0.0039 (95% confidence interval [CI] –
0.0013; 0.0091) and 0.0052 (95% CI –0.0078; 0.018) for ktrans, and 0.046 (95% CI –0.021; 0.11) and 0.069 (95% CI –
0.017; 0.15) for kep, respectively.
All perfusion parameters were not significantly different between groups (P-values: 0.32; 0.47 for ktrans, and 0.24; 0.15)
for kep. However, a significant difference in variance between populations was observed for ktrans (P-value 0.007).
Data Conclusion: Higher patellar bone perfusion parameters were found in patients with PFP when compared to
healthy control subjects, but these differences were not statistically significant. This result, and the observed significant
difference in ktrans variance, warrant further research.
Level of Evidence: 1
Technical Efficacy: Stage 3
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Patellofemoral pain (PFP) is a common knee complaint,especially in young physically active individuals,1 and is
characterized by retropatellar or peripatellar pain during
kneeling, stair climbing, running, cycling, squatting, and
prolonged sitting with the knees flexed. A substantial per-
centage of patients with PFP experience persistent symp-
toms.2,3 While the pathophysiology of PFP is still unknown
and, consequently, targeted therapy is lacking,4–7 an increas-
ing body of research suggests that altered perfusion might
play a role. Both impaired arterial inflow and impaired
venous outflow of blood have been implicated in the devel-
opment of PFP.8–14
Contemporary imaging enables quantitative measure-
ment of perfusion. For instance, dynamic contrast-enhanced
(DCE) magnetic resonance imaging (MRI) is routinely
applied in clinical practice for tumor and cerebral stroke
imaging.15,16 Although DCE-MRI can also be applied to
bone, there have only been a limited number of published
DCE-MRI studies for bone and even fewer that used a quan-
titative approach on MRI data of the lower extremity in
humans.17–22 This might be due to major challenges for the
implementation of quantitative DCE-MRI in bone, such as
the relatively poor vascularization of bone and the typical low
contrast enhancement compared to surrounding tissues.
In order to adequately measure perfusion parameters,
MRI data have to be extracted and fitted by a pharmacoki-
netic model that suits the MRI data. Poot et al25 recently
published a study comparing multiple pharmacokinetic
models, such as Brix et al,23 Tofts and Kermode,24 and
extended Tofts’ model, applied on DCE-MRI of the patellar
bone, in which the Tofts’ model was identified as the best
model.25 Until now, this quantitative DCE-MRI approach
has not been applied in a clinical setting in a large cohort.
Application of this method in a large cohort of patients
with PFP and control subjects may lead to a better under-
standing of the pathophysiology of PFP.
Therefore, the purpose of this study was to investigate
differences in patellar bone blood perfusion, measured with
quantitative DCE-MRI, between patients with PFP and
control subjects.
Materials and Methods
Study Design and Participants
For the current study purpose, patients aged 18–40 years with PFP
and healthy control subjects were included between January 2013
and September 2014. Patients with PFP for 2 months to 2 years
diagnosed by their general practitioner, physiotherapist, or sports
physician, based on the presence of at least three of the following
symptoms: crepitus or retropatellar or peripatellar pain during stair
climbing, squatting, running, cycling, or sitting for a prolonged
period with flexed knees were included.26 Exclusion criteria were:
previous PFP episodes more than 2 years ago, onset after trauma,
defined pathological condition of the affected knee at present, for
instance patellar tendinopathy or Osgood-Schlatter disease, or pre-
vious surgery or injury of the affected knee. Healthy controls were
recruited from patients’ sports team members, friends, or col-
leagues. We sought to match patient and controls on age, gender,
body mass index (BMI), and activity level. Exclusion criteria for
controls were: present or past PFP, surgery or traumatic injury of
both knees, or first-degree relatedness with patients. Other exclu-
sion criteria were: contraindications for contrast-enhanced MRI
and insufficient knowledge of the Dutch language. Written
informed consent was obtained and this study was approved by
our Institutional Review Board.
Measurements
Participants completed a questionnaire on demographics, sports
participation (yes/no), and knee complaints (duration, bilateral
pain, Anterior Knee Pain Scale [AKP]) 0–10027 and underwent 3T
MRI (Discovery MR750, GE Healthcare, Milwaukee, WI) using a
dedicated 8-channel knee coil (InVivo, Gainesville, FL) at our
institution. The (most) symptomatic knee of PFP patients was
selected, or randomly chosen if both knees were equally painful or
if both were asymptomatic (controls). The MRI protocol consisted
of routine clinical proton density and T2-weighted fat-saturated
sequences in three orthogonal planes, and a 3D spoiled gradient-
echo (SPGR) sequence with in-plane resolution of 0.29mm. DCE-
MRI was acquired, consisting of a sagittal, anterior-posterior, fre-
quency-encoded, fat-suppressed 3D SPGR sequence, 35 phases of
10 seconds with intravenous contrast administration (0.2 mmol/kg
Magnevist; Bayer, Berlin, Germany) at 2ml/s starting after the first
phase. Other parameters were: field of view 38 3 38 cm, acquisi-
tion matrix of 256 3 128, zero filled to 256 3 256, in-plane reso-
lution 1.5mm, slice thickness 5mm.
Image Analysis
DCE-MRI measures the amount of contrast enhancement, based
on signal intensity, over time in a specific volume of interest (VOI)
as a measure of blood perfusion.22 Our VOI consisted of the entire
patellar bone marrow (Fig. 1), which was manually delineated on
the 3D SPGR nonfat-saturated MR images with MatLab (R2011a,
MathWorks, Natick, MA) by an experienced blinded observer.28,29
Elastix was used to correct for rigid motion of the patella during
MRI acquisition as well as to rigidly map the DCE acquisition to
the SPGR.30 Perfusion was visualized semiquantitatively by means
of a time–intensity curve. Since a groupwise AIF was used, the
delay between the arterial input function and the start of contrast
enhancement incorporated both dispersion/delay of the contrast
between injection and arrival in the patella as well as injection
time differences. Thus, time–intensity curves were synchronized to
facilitate comparison. Per subject, the mean of the synchronized
time–intensity curve was computed over the VOI. Subsequently,
these were normalized to baseline intensity and the group mean
and 95% confidence interval (CI) were computed. Furthermore,
quantitative analyses were performed by fitting a pharmacokinetic
mode.24 Tofts’ model combined with a groupwise arterial input
function (AIF) was applied, since this combination best fits the
patellar bone according to the recent study by Poot et al.31 This
model uses the AIF from the popliteal artery and assumes one tis-
sue compartment and one vascular compartment (Fig. 2).24 Ktrans
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reflects the volume transfer constant into the tissue compartment,
while kep describes the rate constant back to the vascular compo-
nent. Voxelwise fitting was performed using a maximum-likelihood
(ML) estimator,32 which takes into account the differences in time
required for the contrast agent to reach each voxel.24 Goodness of
fit was assessed by comparing the residual over the entire dataset to
the acquisition noise level. To aggregate the voxelwise perfusion
parameters over the VOI, both weighted means and unweighted
medians were computed. For the weighted mean, the reciprocal
Cramer-Rao-Lower-Bound (indicating fit uncertainty) was used as
weight, in order to assign a lower weight to voxels with high fit
uncertainty and obtain a minimum-variance estimate of the VOI
mean.31 Since this uncertainty-based weight is dependent on the
degree of blood perfusion (better perfused areas have a better fit)
and could therefore be biased, we additionally calculated the
medians of both perfusion parameters, henceforth referred to as
“unweighted” median for the avoidance of doubt. Thus, weighted
mean and unweighted median of ktrans and kep over the VOI in
each participant were computed and these VOI measures of ktrans
and kep were used in the group comparisons.
Statistical Analysis
Independent sample t-tests and chi-square tests, or Mann–Whitney
U-test if distribution was not normal, were applied to investigate
differences in baseline characteristics between groups. Differences
in perfusion parameters (kep and ktrans) were compared between
groups by linear regression analyses, adjusted for age, gender, BMI,
and sports participation. Logarithmic transformations of weighted
mean and median ktrans were performed to acquire normal distri-
butions. Due to the presence of negative values, median kep was
not transformed logarithmically, but tested nonparametrically with
a Mann–Whitney U-test. Differences in variance of perfusion
parameters across subjects were tested with Levene’s test. Additional
adjusted regression analyses were conducted to investigate differ-
ences in perfusion parameters between patients with and without
sitting pain. Item 8 of the AKP score was used to define sitting
pain. Two categories were formed from five possible responses: 1)
no sitting pain (“no difficulty” or “pain after exercise”); and 2) sit-
ting pain (“constant pain,” “pain forces to extend the knees tempo-
rarily,” or “unable”). Furthermore, correlation between perfusion
parameters and AKP score was assessed in patients using Pearson’s
correlation coefficient in case of normal distribution and Spear-
man’s correlation if not. We calculated mean, standard deviation
(SD), and mean differences with 95% CIs. P-values < 0.05 were
considered statistically significant. All analyses were performed with
SPSS v. 20.0 (Chicago, IL).
Results
Participants
Thirty-five adult PFP patients and 44 adult control subjects
were included in this analysis, since DCE-MRI data were
only acquired in adult participants. Mean age was 26.1
(range 18–40, SD 5.0) years, mean BMI was 24.1 (SD 3.4)
kg/m2 and 49% were female. The BMI was significantly
higher in the patient group (Table 1). Patients reported a
mean duration of complaints of 11.2 months and 45.7%
reported bilateral pain. Mean AKP score of patients was 68.
77.1% of the patients reported the presence of sitting pain.
DCE-MRI
The pharmacokinetic model captured the dynamic signal
over the entire dataset and the residual was close to the
acquisition noise level.
Figure 3 shows the normalized mean time–intensity
curves for patients and controls. The curve of the patient
group appeared to have a slightly larger amplitude compared
to controls. The rest of the shape of the curve was not
noticeably different between groups. 95% CIs of the curves
showed an overlap over the entire trajectory.
Quantitative analysis demonstrated a group mean of
weighted mean ktrans of 0.017 (SD 0.014)min
21 for patients
and 0.013 (SD 0.008)min21 for control subjects. The
group mean of the weighted mean kep was 0.19 (SD
0.16)min21 for patients and 0.14 (SD 0.14)min21 for con-
trol subjects. The group mean of unweighted median ktrans
was 0.029 (SD 0.028)min21 for patients and 0.023 (SD
0.030)min21 for control subjects. The group mean of the
unweighted median kep was 0.19 (SD 0.23)min
21 for
patients and 0.11 (SD 0.16)min21 for control subjects
FIGURE 1: Single slice of the VOI of the patellar bone marrow.
FIGURE 2: Schematic representation of Tofts’ pharmacokinetic
model.
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(Table 2, Fig. 4). The means of both quantitative perfusion
parameters were not statistically significantly different
between patients and control subjects and the same applied
to the median (Table 2). The spread of unweighted median
values across subjects was larger than the spread in weighted
mean values (Table 2, Fig. 4). A significant difference in
variance across subjects of weighted mean ktrans was
observed between populations (P5 0.007).
Additional analyses with respect to AKP score showed
no significant correlation between perfusion parameters and
AKP score (Table 3). Furthermore, no significant differences
in perfusion parameters between patients with and without
pain during sitting were demonstrated (data not shown).
Discussion
This case–control study showed higher values of quantitative
DCE-MRI-derived perfusion parameters in patellar bone in
PFP patients compared to healthy control subjects, but these
differences were not statistically significant. This suggests that
patients with PFP do not seem to have a reduced arterial blood
inflow or reduced venous outflow, as previously suggested,8–14
since this would have been reflected by lower perfusion values.
The larger variance of weighted mean ktrans in patients
compared to controls, comprising higher ktrans values in par-
ticular, suggests that a subgroup with higher ktrans values
might exist within the patient population. Higher ktrans val-
ues correspond with hyperperfusion; more blood flowing
into the patellar bone marrow. This might lead to an
increased intraosseous pressure in patients with higher arte-
rial inflow and normal venous outflow, which is supposed
to cause pain by stimulation of baroreceptors. Therefore,
the cause of hyperperfusion needs to be studied further.
Hypervascularization could be a possible explanation for
hyperperfusion. It has been hypothesized by Sanchis-Alfonso
et al that episodes of ischemia, possibly due to vascular tor-
sion during sitting, could trigger hypervascularization of the
patellar retinaculum in maltracking patients with PFP as a
result of increased vascular endothelial growth factor
release.33 This might also be applicable for the patellar
bone. Another explanation for hyperperfusion could be the
presence of bone marrow lesions (BMLs). Lee et al demon-
strated increased blood inflow and impaired “washout,”
which can be interpreted as stasis or outflow obstruction, in
BMLs compared to normal bone in adult patients with oste-
oarthritis or avascular necrosis with painful bone marrow
edema.19 Additional analysis concerning possible patient
subgroups, ie, sitting pain or low AKP score, did not show
significant differences. However, with respect to sitting pain,
only eight patients of 35 had no sitting pain, and thus there
was a lack of power. Future research might focus on the
TABLE 1. Characteristics of Study Participants
Patients
(N5 35)
Controls
(N5 44)
P-value
Female gender n (%) 18 (51.4) 21 (47.7) 0.74
Age (years) Mean (SD) 26.4 (5.6) 25.9 (4.6) 0.53
BMI (kg/m2) Mean (SD) 25.1 (3.8) 23.3 (2.8) 0.01
Sports participants 0.39
during inclusion n (%) 24 (68.6) 34 (77.3)
before onset of pain n (%) 32 (91.4) n.a.
Duration of complaints Mean (SD) 11.2 (6.3) n.a. n.a.
Bilateral pain n (%) 16 (45.7) n.a. n.a.
AKP score Mean (SD) 68.6 (11.0) n.a. n.a.
Sitting pain n (%) 27 (77.1) 0 (0) n.a.
n.a.: not applicable.
FIGURE 3: Normalized mean synchronized time–intensity curves
and corresponding 95% CIs for patients and controls.
Journal of Magnetic Resonance Imaging
4 Volume 00, No. 00
correlation between (combinations of ) morphologic parame-
ters and specific perfusion patterns and/or on perfusion of
other patellofemoral joint tissues.
The aforementioned study of Poot et al optimized the
DCE-MRI method for patellar bone in a small subset, but
did not apply this method in a large cohort in a clinical set-
ting.31 One previous study has evaluated blood perfusion of
bone of the knee joint in humans using a quantitative DCE-
MRI approach in a clinical setting.17 Seah et al applied quan-
titative DCE-MRI in knee osteoarthritis patients and found
no association between perfusion of tibial BMLs and pain.17
Their results, however, cannot be directly compared to ours.
This is mainly due to the use of a different pharmacokinetic
model, Brix instead of Tofts, a different region of interest, tib-
ial BMLs instead of patellar bone, and the fact that they stud-
ied bone marrow lesions and not normal bone. Two other
studies used Tofts’ model in the femur, showing quite differ-
ent values compared to ours, likely explained by a different
blood perfusion between femur and patella.20,21
A major strength and novelty of this study is the
application of a tailored quantitative DCE-MRI approach in
a large number of relatively young individuals with and
without PFP. Furthermore, in contrast to previous studies,
an optimized method for patellar DCE-MRI data was used
as proposed by Poot et al.31
There are also some limitations that need to be addressed.
It is important to place these into perspective, however, since
TABLE 2. Group Mean and Standard Deviation of Weighted Mean Over VOI for kep and ktrans (min
21) and Group
Mean and Standard Deviation of Unweighted Median Over VOI kep and ktrans of Patellar Bone in Patients and
Controls
Patients
(N5 35)
Controls
(N5 44)
Mean difference
(95% CI)
Adjusted
P-value
Ktrans (min
21)
Weighted mean 0.017 (0.014) 0.013 (0.008) 0.0039 (–0.0013 ; 0.0091) 0.32
Unweighted median 0.029 (0.028) 0.023 (0.030) 0.0052 (–0.0078 ; 0.018) 0.47
Kep (min
21)
Weighted mean 0.19 (0.16) 0.14 (0.14) 0.046 (–0.021 ; 0.11) 0.24
Unweighted median 0.19 (0.23) 0.11 (0.16) 0.069 (–0.017 ; 0.15) 0.15a
All were adjusted for age, gender, BMI and sports participation. CI: confidence interval.
aNonparametric testing.
FIGURE 4: Boxplots of weighted mean and unweighted median
ktrans and kep (min
21) subdivided in patients and controls.
TABLE 3. Correlation Between the AKP Score and
Weighted Mean of kep and ktrans (min
21) and
Unweighted Median of kep and ktrans of Patellar Bone
in Patients
Correlation
coefficient
P-value
Ktrans (min
21)
Weighted mean 0.20 0.25a
Unweighted median 0.14 0.42a
Kep (min
21)
Weighted mean 0.02 0.93
Unweighted median 0.02 0.92a
aNonparametric testing.
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DCE-MRI of bone is novel and is still an emerging field of
research posing significant challenges. First, although we aimed
to match patients and controls on age, gender, BMI, and sports
participation, differences were observed in BMI. Therefore, all
analyses, besides median kep, were adjusted for these confound-
ers. Adjustment for confounders was not possible for median
kep, due to nonparametric testing. However, as all confounders
in the regression analysis of median kep were not statistically
significant and had low regression coefficients, we believe that
the Mann–Whitney U-test was used appropriately. Second,
histograms showed a high spatial heterogeneity of patellar
blood perfusion, which could potentially lead to a biased
weighted mean due to underweighting of less-perfused areas.
Therefore, we decided to additionally calculate the unweighted
medians of both perfusion parameters. The results showed
indeed a small difference between the group mean of the
weighted mean and the unweighted median. Weighting was
implemented in order to obtain a minimum-variance estimate
of the VOI mean,31 although, and as expected, the weighted
mean had a lower variance compared to the unweighted
median. Consequently, since no ground truth is available, anal-
yses took place on both values. It was expected that if large areas
of altered perfusion were present, this would have emerged in
one of these values. Additionally, based on the high spatial het-
erogeneity, segmenting the patella into subregions would have
been of interest; however, this was not possible due to spatial
resolution restrictions. Finally, a large intersubject variability,
possibly caused by measurement variability or normal tissue
heterogeneity, makes detecting small but significant differences
more difficult. We were not able to disentangle measurement
variability and normal tissue heterogeneity due to the fact that
studying reproducibility of DCE-MRI is not feasible in a
human population because of the burden of repeated contrast
administration. However, Poot et al previously showed that
with this DCE-MRI method, reproducibility is sufficient to
allow identification of group differences in perfusion of 10%
in ktrans or kep at a significance level of P< 0.05 with 75%
power with our sample size.31 Given the new insight of high
intersubject variability, however, and the fact that the minimal
clinical relevant difference is unknown, a larger sample size
could be needed to make sure small, yet significant differences
are not missed.
In conclusion, higher values of patellar bone perfusion
parameters, measured with quantitative DCE-MRI, were
found in PFP patients compared to healthy control subjects,
but these differences were not statistically significant. This
result, and the observed significant difference in ktrans vari-
ance, warrant further research.
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